TACSTD2 and adenocarcinoma: Because TROP2 is a promising molecular target for the treatment of lung cancer, we examined the association of TROP2 expression with clinicopathological and molecular features as well as with prognosis of various lung cancer subtypes, including 270 consecutive cases of adenocarcinoma, 201 cases of SqCC, and 115 cases of HGNET (74 cases of SCLC and 41 cases of LCNEC).